Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Common Equity (2018 - 2025)

10x Genomics (TXG) has disclosed Common Equity for 8 consecutive years, with $796.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 12.14% to $796.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $796.3 million through Dec 2025, up 12.14% year-over-year, with the annual reading at $796.3 million for FY2025, 12.14% up from the prior year.
  • Common Equity hit $796.3 million in Q4 2025 for 10x Genomics, up from $785.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $817.6 million in Q4 2021 to a low of $706.9 million in Q1 2025.
  • Historically, Common Equity has averaged $767.3 million across 5 years, with a median of $779.7 million in 2022.
  • Biggest five-year swings in Common Equity: skyrocketed 100.52% in 2021 and later dropped 10.41% in 2024.
  • Year by year, Common Equity stood at $817.6 million in 2021, then dropped by 1.45% to $805.7 million in 2022, then decreased by 8.03% to $741.0 million in 2023, then fell by 4.17% to $710.1 million in 2024, then grew by 12.14% to $796.3 million in 2025.
  • Business Quant data shows Common Equity for TXG at $796.3 million in Q4 2025, $785.1 million in Q3 2025, and $773.3 million in Q2 2025.